CHEK2 anticorps (AA 481-531)
-
- Antigène Voir toutes CHEK2 Anticorps
- CHEK2 (Checkpoint Kinase 2 (CHEK2))
-
Épitope
- AA 481-531
-
Reactivité
- Humain
-
Hôte
- Souris
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp CHEK2 est non-conjugé
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunocytochemistry (ICC)
- Fonction
- CHK2 Antibody
- Purification
- Ascitic fluid
- Immunogène
- Purified recombinant fragment of human CHK2 (aa481-531) expressed in E. Coli.
- Clone
- 1C12B8
- Isotype
- IgG2b
- Top Product
- Discover our top product CHEK2 Anticorps primaire
-
-
- Indications d'application
-
ELISA: 1/10000
ICC: 1/200 - 1/1000
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Ascitic fluid containing 0.03 % sodium azide.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C,-20 °C
- Stockage commentaire
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
-
-
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. ..." dans: Carcinogenesis, Vol. 29, Issue 4, pp. 762-5, (2008) (PubMed).
: "CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?" dans: Nature reviews. Cancer, Vol. 7, Issue 12, pp. 925-36, (2007) (PubMed).
: "Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts." dans: International journal of cancer. Journal international du cancer, Vol. 121, Issue 12, pp. 2661-7, (2007) (PubMed).
: "
-
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. ..." dans: Carcinogenesis, Vol. 29, Issue 4, pp. 762-5, (2008) (PubMed).
-
- Antigène
- CHEK2 (Checkpoint Kinase 2 (CHEK2))
- Autre désignation
- CHK2 (CHEK2 Produits)
- Synonymes
- anticorps CDS1, anticorps CHK2, anticorps HuCds1, anticorps LFS2, anticorps PP1425, anticorps RAD53, anticorps hCds1, anticorps fa66f08, anticorps wu:fa66f08, anticorps zgc:55865, anticorps Cds1, anticorps HUCDS1, anticorps Rad53, anticorps Chk2, anticorps cds1, anticorps chek2, anticorps chk2, anticorps hucds1, anticorps lfs2, anticorps pp1425, anticorps rad53, anticorps checkpoint kinase 2, anticorps serine/threonine-protein kinase chk2, anticorps checkpoint kinase 2 L homeolog, anticorps CHEK2, anticorps chek2, anticorps Chek2, anticorps MCYG_07308, anticorps chek2.L
- Sujet
-
Description: CHK2: CHK2 checkpoint homolog (S. pombe). In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.
Aliases: CDS1, LFS2, CHEK2
- Poids moléculaire
- 61kDa
- ID gène
- 11200
- HGNC
- 11200
- UniProt
- O96017
- Pathways
- Signalisation p53, Apoptose, Cycle Cellulaire
-